[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Maze Therapeutics\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":71},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,45],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100645740","phase-2-a-study-of-mze782-in-adults-with-pku-100645740",false,"NCT07694440","A Study of MZE782 in Adults With PKU","A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety, Tolerability, and Efficacy of MZE782 in Adults With Phenylketonuria (PKU)","CIPheR","Key Inclusion Criteria:\n\n* Males and females 18 to 75 years old\n* Clinical diagnosis of PKU\n* Willing and able to keep diet and protein intake consistent during the study\n* For some study groups, is willing and able to stop certain PKU medications before starting study treatment\n* For some study groups, may need to meet additional blood phenylalanine level or background-treatment requirements\n* Meets minimum blood phenylalanine level requirements for study group\n\nKey Exclusion Criteria:\n\n* Is pregnant, breastfeeding, or planning to become pregnant or conceive a child during the study or within 90 days after the last dose\n* Medical conditions or abnormal test results that could make participation unsafe or make it difficult to complete study procedures or interpret study results\n* Has recently received another investigational drug\n* Is unable to swallow tablets or tolerate oral medication\n\nOther inclusion\u002Fexclusion criteria defined in protocol apply.","ALL","18 Years","75 Years",{"count":21,"type":22},38,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","The purpose of this study is to evaluate the safety, tolerability, and efficacy of MZE782 in adults with Phenylketonuria (PKU).",[28],"Phenylketonuria (PKU)",[30,31],"PKU","Phenylketonuria","RECRUITING","2026-08-18",{"date":35,"type":36},"2026-08-20","ACTUAL",{"date":38,"type":36},"2026-06-23",{"date":40,"type":22},"2028-02",{"name":42,"class":43},"Maze Therapeutics","INDUSTRY",6,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":23,"phases":55,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},"100579925","phase-2-a-phase-2-study-of-mze829-in-adults-with-apol1-kidney-disease-100579925","NCT06830629","A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease","An Open-Label Phase 2 Study to Evaluate the Safety, Tolerability, and Effect on Albuminuria of MZE829 in Adults With Proteinuric Chronic Kidney Disease and the APOL1 High Risk Genotype","Key Inclusion Criteria:\n\n* APOL1 high risk genotype of G1\u002FG1, G2\u002FG2, or G1\u002FG2\n* Chronic kidney disease with persistent albuminuria\n\nKey Exclusion Criteria:\n\n* Organ or bone marrow transplantation\n* History of active cancer within past 2 years, except for treated non-melanoma skin cancer, stage 0 cervical cancer, or stage 1 prostate cancer\n* Conditions that may alter drug absorption, e.g., history of bariatric surgery\n* Type I diabetes\n* Pregnant or currently nursing\n\nOther inclusion\u002Fexclusion criteria defined in protocol apply.","68 Years",{"count":54,"type":22},74,[25],"The purpose of this study is to evaluate the safety, tolerability, and effect on Albuminuria of MZE829 in Adults with APOL1 Kidney Disease.",[58],"Proteinuric Kidney Disease",[60,61],"APOL1-mediated kidney disease (AMKD)","APOL1 kidney disease (AKD)","2026-07-23",{"date":64,"type":36},"2026-07-27",{"date":66,"type":36},"2025-02-05",{"date":68,"type":22},"2026-09",{"name":42,"class":43},79,""]